Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070 · see citing works

Tolerance of normal tissue to therapeutic irradiation

Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488 · see citing works

Accelerated image reconstruction using ordered subsets of projection data

Hudson, H. M., & Larkin, R. S. (1994) · IEEE Transactions on Medical Imaging · doi:10.1109/42.363108 · Cited by 3,713 · see citing works

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · see citing works

Untitled work

(1997) · PubMed · Cited by 1,541 · see citing works

Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival

Kwekkeboom, D. J., de Herder, W. W., Kam, B. L. R., van Eijck, C. H. J., van Essen, M., Kooij, P. P. M., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,454 · see citing works

Bayesian reconstructions from emission tomography data using a modified EM algorithm

Green, P. J. (1990) · IEEE Transactions on Medical Imaging · doi:10.1109/42.52985 · Cited by 1,242 · see citing works

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions

Afshar‐Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H., Hadaschik, B. A., Holland‐Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 919 · see citing works

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

Ghosh, A., & Heston, W. D. W. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 883 · see citing works

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

Zaknun, J. J., Bodei, L., Mueller‐Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O'Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 823 · see citing works

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

Benešová, M., Schäfer, M. K.-H., Bauder‐Wüst, U., Afshar‐Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 621 · see citing works

Phase I Trial of 177 Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

Bander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoğlu, L., Vallabhajosula, S., & Goldsmith, S. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.160 · Cited by 511 · see citing works

Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Tagawa, S. T., Milowsky, M. I., Morris, M. J., Vallabhajosula, S., Christos, P. J., Akhtar, N. H., Osborne, J. R., Goldsmith, S. J., Larson, S. M., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427 · see citing works

MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy

Dewaraja, Y. K., Frey, E. C., Sgouros, G., Brill, A. B., Roberson, P. L., ZANZONICO, P. B., & Ljungberg, M. H. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.100123 · Cited by 419 · see citing works

Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

Zechmann, C. M., Afshar‐Oromieh, A., Armor, T., Stubbs, J. B., Mier, W., Hadaschik, B. A., Joyal, J. L., Kopka, K., Debus, J., Babich, J. W., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2713-y · Cited by 359 · see citing works

MIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications

Dewaraja, Y. K., Ljungberg, M. H., Green, A. J., ZANZONICO, P. B., Frey, E. C., Bolch, W. E., Brill, A. B., Dunphy, M. P., Fisher, D. R., Howell, R. W., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.122390 · Cited by 335 · see citing works

PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT

Stabin, M. G., & Siegel, J. A. (2003) · Health Physics · doi:10.1097/00004032-200309000-00006 · Cited by 314 · see citing works

Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer

Milowsky, M. I., Nanus, D. M., Kostakoğlu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.154 · Cited by 313 · see citing works

EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry

Hindorf, C., Glatting, G., Chiesa, C., Lindén, O., & Flux, G. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1422-4 · Cited by 300 · see citing works

Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.

Sgouros, G. (1993) · PubMed · Cited by 299 · see citing works

Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177 Lu-DOTA-Octreotate Treatment

Sandström, M., Garske‐Román, U., Granberg, D. O., Johansson, S., Widström, C., Eriksson, B. K., Sundin, A., Lundqvist, H., & Lubberink, M. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107524 · Cited by 287 · see citing works

Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

Wild, D., Fani, M., Fischer, R., Pozzo, L. D., Kaul, F., Krebs, S. S., Fischer, R., Rivier, J., Reubi, J. C., Maëcke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 267 · see citing works

Lutetium-labelled peptides for therapy of neuroendocrine tumours

Kam, B. L. R., Teunissen, J. J. M., Krenning, E. P., de Herder, W. W., Khan, S., van Vliet, E. I., & Kwekkeboom, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2039-y · Cited by 247 · see citing works

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

Forrer, F., Krenning, E. P., Kooij, P. P. M., Bernard, B. F., Konijnenberg, M., Bakker, W. H., Teunissen, J. J. M., de Jong, M., van Lom, K., de Herder, W. W., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1072-6 · Cited by 202 · see citing works

The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer

Pond, G. R., Sonpavde, G., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Armstrong, A. J. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.024 · Cited by 193 · see citing works

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

Vallabhajosula, S., Kuji, I., Hamacher, K. A., Konishi, S., Kostakoğlu, L., Kothari, P. A., Milowsky, M. I., Nanus, D. M., Bander, N. H., & Goldsmith, S. J. (2005) · PubMed · Cited by 129 · see citing works

A generalized model for the conversion from CT numbers to linear attenuation coefficients

Bai, C., Shao, L., Silva, A. J. D., & Zhao, Z. (2003) · IEEE Transactions on Nuclear Science · doi:10.1109/tns.2003.817281 · Cited by 125 · see citing works

Scatter compensation methods in 3D iterative SPECT reconstruction: A simulation study

Beekman, F. J., Kamphuis, C., & Frey, E. C. (1997) · Physics in Medicine and Biology · doi:10.1088/0031-9155/42/8/011 · Cited by 106 · see citing works

Prostate-specific membrane antigen expression in regeneration and repair

Gordon, I. O., Tretiakova, M., Noffsinger, A. E., Hart, J. A. L., Reuter, V. E., & Al‐Ahmadie, H. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.143 · Cited by 89 · see citing works

Parotid gland-recovery after radiotherapy in the head and neck region - 36 months follow-up of a prospective clinical study

Hey, J., Setz, J. M., Gerlach, R., Janich, M., Hildebrandt, G., Vordermark, D., Gernhardt, C. R., & Kuhnt, T. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-125 · Cited by 72 · see citing works

Minor changes in effective half-life during fractionated 177 Lu-Octreotate therapy

Garske, U., Sandström, M., Johansson, S., Sundin, A., Granberg, D. O., Eriksson, B. K., & Lundqvist, H. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.618511 · Cited by 67 · see citing works

Quantitative SPECT/CT Imaging of 177Lu with In Vivo Validation in Patients Undergoing Peptide Receptor Radionuclide Therapy

Sanders, J. C., Kuwert, T., Joachim Hornegger, A., & Ritt, P. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0806-4 · Cited by 64 · see citing works

An optimal rotator for iterative reconstruction

Wallis, J. W., & Miller, T. R. (1997) · IEEE Transactions on Medical Imaging · doi:10.1109/42.552061 · Cited by 59 · see citing works

Yttrium-labelled peptides for therapy of NET

Bodei, L., Cremonesi, M., Grana, C. M., Chinol, M., Baio, S. M., Severi, S., & Paganelli, G. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2002-y · Cited by 55 · see citing works

Influence of total-body mass on the scaling ofS-factors for patient-specific, blood-based red-marrow dosimetry

Traino, C., Ferrari, M. E., Cremonesi, M., & Stabin, M. G. (2007) · Physics in Medicine and Biology · doi:10.1088/0031-9155/52/17/009 · Cited by 51 · see citing works

Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes

Gensheimer, M. F., Liao, J. J., Garden, A. S., Laramore, G. E., & Parvathaneni, U. (2014) · Radiation Oncology · doi:10.1186/s13014-014-0255-x · Cited by 44 · see citing works

The Influence of Early Measurements Onto the Estimated Kidney Dose in [177Lu][DOTA0,Tyr3]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors

Delker, A., Ilhan, H., Zach, C., Brosch-Lenz, J., Gildehaus, F. J., Lehner, S., Bartenstein, P., & Böning, G. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0839-3 · Cited by 41 · see citing works

Comparison of frequency-distance relationship and Gaussian-diffusion-based methods of compensation for distance-dependent spatial resolution in SPECT imaging

Kohli, V., King, M. A., Glick, S. J., & Pan, T.-S. (1998) · Physics in Medicine and Biology · doi:10.1088/0031-9155/43/4/029 · Cited by 37 · see citing works

Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man

Larson, S. M., Raubitschek, A. A., Reynolds, J. C., Neumann, R. D., Hellström, K. E., Hellström, I., Colcher, D. M., Schlom, J., GLATSTEIN, E. J., & Carrasquillo, J. A. (1989) · International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology · doi:10.1016/0883-2897(89)90188-8 · Cited by 23 · see citing works

Prostate-specific membrane antigen expression in the duodenum: implications in coeliac disease and immunotherapy for prostate cancer

Maraj, B. H., Aldersley, M. A., & Markham, A. F. (1998) · The Lancet · doi:10.1016/s0140-6736(05)61125-7 · Cited by 15 · see citing works

The two types of correction of absorbed dose estimates for internal emitters

Williams, L. E., Liu, A., Yamauchi, D. M., Lopatin, G., Raubitschek, A. A., & Wong, J. Y. C. (2002) · Cancer · doi:10.1002/cncr.10290 · Cited by 12 · see citing works

I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

Zechmann, C. M., Afshar‐Oromieh, A., Armor, T., Stubbs, J. B., Mier, W., Hadaschik, B. A., Joyal, J. L., Kopka, K., Debus, J., Babich, J. W., et al. (2014) · Cited by 10 · see citing works

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,163 · see citing works

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷Lu-Labeled PSMA-617

Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636 · see citing works

Current use of PSMA–PET in prostate cancer management

Maurer, T., Eiber, M. J., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 613 · see citing works

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · see citing works

Dosimetry of ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504 · see citing works

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

Kostelnik, T. I., & Orvig, C. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 482 · see citing works

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

Kratochwil, C., Fendler, W. P., Eiber, M., Baum, R. P., Bozkurt, M. F., Czernin, J. G., Bolton, R. C. D., Ezziddin, S., Forrer, F., Hicks, R. J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04485-3 · Cited by 387 · see citing works

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P. J., Lindenberg, L., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06255-8 · Cited by 326 · see citing works

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Emmett, L., Willowson, K. P., Violet, J. A., Shin, J., Blanksby, A., & Lee, J. (2017) · Journal of Medical Radiation Sciences · doi:10.1002/jmrs.227 · Cited by 305 · see citing works

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

Heck, M. M., Tauber, R., Schwaiger, S., Retz, M. M., D’Alessandria, C., Maurer, T., Gafita, A., Wester, H., Gschwend, J. E., Weber, W., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.11.016 · Cited by 299 · see citing works

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

Violet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292 · see citing works

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Ahmadzadehfar, H., Eppard, E., Kürpig, S., Fimmers, R., Yordanova, A., Schlenkhoff, C. D., Gärtner, F., Rogenhofer, S., & Essler, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7245 · Cited by 282 · see citing works

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Gleisner, K. S., Chouin, N., Gabiña, P. M., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05727-7 · Cited by 272 · see citing works

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer

Afshar‐Oromieh, A., Babich, J. W., Kratochwil, C., Giesel, F. L., Eisenhut, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170720 · Cited by 259 · see citing works

Preclinical Evaluation of 18 F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging

Cardinale, J., Schäfer, M. K.-H., Benešová, M., Bauder‐Wüst, U., Leotta, K., Eder, M., Neels, O. C., Haberkorn, U., Giesel, F. L., & Kopka, K. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.181768 · Cited by 255 · see citing works

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

Eiber, M. J., Fendler, W. P., Rowe, S. P., Calais, J., Hofman, M. S., Maurer, T., Schwarzenboeck, S. M., Kratowchil, C., Herrmann, K., & Giesel, F. L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186767 · Cited by 243 · see citing works

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Fendler, W. P., Reinhardt, S., Ilhan, H., Delker, A., Böning, G., Gildehaus, F. J., Stief, C. G., Bartenstein, P., Gratzke, C., Lehner, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12240 · Cited by 222 · see citing works

Radiation Dosimetry for ¹⁷⁷ Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions

Okamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178483 · Cited by 213 · see citing works

Response and Tolerability of a Single Dose of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis

Rahbar, K., Schmidt, M. C., Heinzel, A., Eppard, E., Bode, A., Yordanova, A., Claesener, M., & Ahmadzadehfar, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173757 · Cited by 213 · see citing works

177Lu-PSMA Radioligand Therapy for Prostate Cancer

Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191023 · Cited by 206 · see citing works

44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617

Umbricht, C. A., Benešová, M., Schmid, R. M., Türler, A., Schibli, R., van der Meulen, N. P., & Müller, C. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0257-4 · Cited by 192 · see citing works

Systemic Radioligand Therapy with 177 Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

Heck, M. M., Retz, M. M., D’Alessandria, C., Rauscher, I., Scheidhauer, K., Maurer, T., Storz, E., Janssen, F., Schottelius, M., Wester, H., et al. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.02.2969 · Cited by 187 · see citing works

Prostate-Specific Membrane Antigen Radioligand Therapy Using 177 Lu-PSMA I&T and 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

Schuchardt, C., Zhang, J., Kulkarni, H., Chen, X. S., Müller, D., & Baum, R. P. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262713 · Cited by 187 · see citing works

Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer

Rahbar, K., Bode, A., Weckesser, M., Avramović, N., Claesener, M., Stegger, L., & Bögemann, M. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001240 · Cited by 186 · see citing works

Radioligand Therapy With 177 Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Yadav, M. P., Ballal, S., Sahoo, R. K., Dwivedi, S. N., & Bal, C. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.18.20845 · Cited by 184 · see citing works

TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)

Hofman, M. S., Emmett, L., Violet, J. A., Zhang, A. Y., Lawrence, N. J., Stockler, M. R., Francis, R. J., Iravani, A., Williams, S., Azad, A., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14876 · Cited by 165 · see citing works

Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities

Fendler, W. P., Pabst, K. M., Kessler, L., Costa, P. F., Ferdinandus, J., Weber, M., Lippert, M., Lückerath, K., Umutlu, L., Kostbade, K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1432 · Cited by 165 · see citing works

Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers

Kopka, K., Benešová, M., Bařinka, C., Haberkorn, U., & Babich, J. W. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186775 · Cited by 161 · see citing works

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment

Yadav, M. P., Ballal, S., Tripathi, M., Damle, N. A., Sahoo, R. K., Seth, A., & Bal, C. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3481-7 · Cited by 147 · see citing works

First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer

Kurth, J., Krause, B. J., Schwarzenböck, S. M., Bergner, C., Hakenberg, O. W., & Heuschkel, M. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04504-3 · Cited by 147 · see citing works

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer

Eppard, E., de la Fuente, A., Benešová, M., Khawar, A., Bundschuh, R. A., Gärtner, F., Kreppel, B., Kopka, K., Essler, M., & Rösch, F. (2017) · Theranostics · doi:10.7150/thno.20586 · Cited by 140 · see citing works

Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors

Jackson, P. A., Hofman, M. S., Hicks, R. J., Scalzo, M., & Violet, J. A. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233411 · Cited by 138 · see citing works

The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer

Yordanova, A., Becker, A., Eppard, E., Kürpig, S., Fisang, C., Feldmann, G., Essler, M., & Ahmadzadehfar, H. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3681-9 · Cited by 134 · see citing works

First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Zang, J., Fan, X., Wang, H., Liu, Q., Wang, J., Li, H. Y., Li, F., Jacobson, O., Niu, G., Zhu, Z., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4096-y · Cited by 132 · see citing works

Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy

Wüstemann, T., Haberkorn, U., Babich, J. W., & Mier, W. (2018) · Medicinal Research Reviews · doi:10.1002/med.21508 · Cited by 123 · see citing works

Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer

Kim, Y. J., & Kim, Y.-I. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002210 · Cited by 118 · see citing works

The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates

Scarpa, L., Buxbaum, S., Kendler, D., Fink, K., Bektić, J., Gruber, L. N., Decristoforo, C., Uprimny, C., Lukas, P. H., Horninger, W., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3609-9 · Cited by 117 · see citing works

Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy

Chen, H., Zhao, L., Fu, K., Lin, Q., Wen, X., Jacobson, O., Sun, L., Wu, H., Zhang, X., Guo, Z., et al. (2019) · Theranostics · doi:10.7150/thno.39203 · Cited by 117 · see citing works

Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

Yadav, M. P., Ballal, S., Bal, C., Sahoo, R. K., Damle, N. A., Tripathi, M., & Seth, A. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002833 · Cited by 115 · see citing works

Theranostic radiopharmaceuticals: established agents in current use

Ballinger, J. R. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170969 · Cited by 114 · see citing works

Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom

Fendler, W. P., Kratochwil, C., Ahmadzadehfar, H., Rahbar, K., Baum, R. P., Schmidt, M. C., Pfestroff, A., Lützen, U., Prasad, V., Heinzel, A., et al. (2016) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0037-1616480 · Cited by 113 · see citing works

External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies

Kurth, J., Krause, B. J., Schwarzenböck, S. M., Stegger, L., Schäfers, M. A., & Rahbar, K. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0386-4 · Cited by 109 · see citing works

Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

Czerwińska, M., Bilewicz, A., Kruszewski, M. K., Węgierek-Ciuk, A., & Lankoff, A. (2020) · Molecules · doi:10.3390/molecules25071743 · Cited by 109 · see citing works

PSMA PET and Radionuclide Therapy in Prostate Cancer

Bouchelouche, K., Türkbey, B., & Choyke, P. L. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.07.006 · Cited by 101 · see citing works

Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study

Privé, B. M., Peters, S. M. B., Muselaers, S., van Oort, I. M., Janssen, M. J. R., Sedelaar, J. P. M., Konijnenberg, M., Zámecnik, P., Uijen, M. J. M., Schilham, M. G. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4298 · Cited by 100 · see citing works

The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far

Heynickx, N., Herrmann, K., Vermeulen, K., Baatout, S., & Aerts, A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.04.003 · Cited by 100 · see citing works

Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides

Morgan, K. A., Rudd, S. E., Noor, A., & Donnelly, P. S. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00456 · Cited by 100 · see citing works

Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer

Gaertner, F. C., Halabi, K., Ahmadzadehfar, H., Kürpig, S., Eppard, E., Kotsikopoulos, C., Liakos, N., Bundschuh, R. A., Strunk, H. M., & Essler, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19049 · Cited by 100 · see citing works

99mTc‐MIP‐1404‐SPECT/CT for the detection of PSMA‐positive lesions in 225 patients with biochemical recurrence of prostate cancer

Schmidkonz, C., Hollweg, C., Beck, M., Reinfelder, J., Goetz, T. I., Sanders, J. C., Schmidt, D., Prante, O., Bäuerle, T., Cavallaro, A., et al. (2017) · The Prostate · doi:10.1002/pros.23444 · Cited by 99 · see citing works

Targeted Alpha Therapy: Current Clinical Applications

Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3576 · Cited by 99 · see citing works

Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04

Kuyumcu, S., Kovan, B., Şanlı, Y., Büyükkaya, F., Şimşek, D. H., Özkan, Z. G., Işık, E. G., Ekenel, M., & Türkmen, C. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003667 · Cited by 99 · see citing works

Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95 · see citing works

The Use of the Macrocyclic Chelator DOTA in Radiochemical Separations

Baranyai, Z., Tircsó, G., & Rösch, F. (2019) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201900706 · Cited by 95 · see citing works

Towards standardization of absolute SPECT/CT quantification: a multi-center and multi-vendor phantom study

Peters, S. M. B., van der Werf, N. R., Segbers, M., van Velden, F. H. P., Wierts, R., Blokland, K. A. K., Konijnenberg, M., Lazarenko, S. V., Visser, E. P., & Gotthardt, M. (2019) · EJNMMI Physics · doi:10.1186/s40658-019-0268-5 · Cited by 93 · see citing works

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

Lückerath, K., Liu, W., Fendler, W. P., Axelsson, S. E., Stuparu, A. D., Slavik, R., Mona, C. E., Calais, J., Rettig, M. B., Reiter, R. E., et al. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0451-z · Cited by 91 · see citing works

Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

Rudisile, S., Gosewisch, A., Wenter, V., Unterrainer, M., Böning, G., Gildehaus, F. J., Fendler, W. P., Auernhammer, C. J., Spitzweg, C., Bartenstein, P., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6000-y · Cited by 91 · see citing works

Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome

Peters, S. M. B., Privé, B. M., de Bakker, M., de Lange, F., Jentzen, W., Eek, A., Muselaers, C. H. J., Mehra, N., Witjes, J. A., Gotthardt, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05471-4 · Cited by 88 · see citing works

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617

Umbricht, C. A., Köster, U., Bernhardt, P., Gracheva, N., Johnston, K., Schibli, R., van der Meulen, N. P., & Müller, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-54150-w · Cited by 88 · see citing works

Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617

Hohberg, M., Eschner, W., Schmidt, M. C., Dietlein, M., Kobe, C., Fischer, T. H., Drzezga, A. E., & Wild, M. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0942-0 · Cited by 85 · see citing works

Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry

Kabasakal, L., Toklu, T., Yeyin, N., Demirci, E., Abuqbeitah, M., Ocak, M., Aygün, A., Karayel, E., Pehlivanoğlu, H., & Selçuk, N. A. (2017) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/mirt.08760 · Cited by 85 · see citing works

Toward Single-Time-Point Image-Based Dosimetry of177Lu-PSMA-617 Therapy

Brosch-Lenz, J., Delker, A., Völter, F., Unterrainer, L. M., Kaiser, L., Bartenstein, P., Ziegler, S. I., Rahmim, A., Uribe, C., & Böning, G. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264594 · Cited by 84 · see citing works

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

Afshar‐Oromieh, A., Haberkorn, U., Zechmann, C. M., Armor, T., Mier, W., Spohn, F., Debus, N., Holland‐Letz, T., Babich, J. W., & Kratochwil, C. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3665-9 · Cited by 82 · see citing works

PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?

Taïeb, D., Foletti, J. M., Bardiès, M., Rocchi, P., Hicks, R. J., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.207993 · Cited by 82 · see citing works

Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq

Rathke, H. G., Giesel, F. L., Flechsig, P., Kopka, K., Mier, W., Hohenfellner, M., Haberkorn, U., & Kratochwil, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194209 · Cited by 81 · see citing works

Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors

Kelly, J., Amor‐Coarasa, A., Ponnala, S., Nikolopoulou, A., Williams, C. M., Schlyer, D. J., Zhao, Y., Kim, D., & Babich, J. W. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4004-5 · Cited by 81 · see citing works

Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer

Kratochwil, C., Afshar‐Oromieh, A., Kopka, K., Haberkorn, U., & Giesel, F. L. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.04.004 · Cited by 80 · see citing works

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer

Yadav, M. P., Ballal, S., Tripathi, M., Damle, N. A., Sahoo, R. K., Seth, A., & Bal, C. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000606 · Cited by 79 · see citing works

The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides

Begum, N. J., Thieme, A., Eberhardt, N., Tauber, R., D’Alessandria, C., Beer, A. J., Glatting, G., Eiber, M. J., & Kletting, P. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203505 · Cited by 78 · see citing works

Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer

Pillai, M. R. A., Nanabala, R., Joy, A., Sasikumar, A., & Knapp, F. F. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.08.006 · Cited by 77 · see citing works

Renal and Multiorgan Safety of 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Herrmann, K., Rahbar, K., Eiber, M., Sparks, R. B., Baca, N., Krause, B. J., Laßmann, M., Jentzen, W., Tang, J., Chicco, D., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265448 · Cited by 77 · see citing works

Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose

Lawhn-Heath, C., Hope, T. A., Martinez, J., Fung, E. K., Shin, J., Seo, Y., & Flavell, R. R. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00657-4 · Cited by 75 · see citing works

[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment

Peters, S. M. B., Hofferber, R., Privé, B. M., de Bakker, M., Gotthardt, M., Janssen, M. J. R., de Lange, F., Muselaers, S., Mehra, N., Witjes, J. A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05538-2 · Cited by 75 · see citing works

Radionuclide Therapy of Metastatic Prostate Cancer

Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.02.003 · Cited by 74 · see citing works

Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC

Kramer, V., Fernández, R., Lehnert, W., Jiménez‐Franco, L. D., Soza‐Ried, C., Eppard, E., Ceballos, M., Meckel, M., Benešová, M., Umbricht, C. A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05022-3 · Cited by 73 · see citing works

Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges

Bakht, M. K., Oh, S. W., Youn, H., Cheon, G. J., Kwak, C. H., & Kang, K. W. (2016) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-016-0439-4 · Cited by 70 · see citing works

Dosimetry of [177Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis

Ells, Z., Grogan, T., Czernin, J. G., Dahlbom, M., & Calais, J. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267452 · Cited by 68 · see citing works

Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer

Baratto, L., Duan, H., Mäcke, H. R., & Iagaru, A. H. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234971 · Cited by 67 · see citing works

Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems

Peters, S. M. B., Viol, S. L. M., van der Werf, N. R., de Jong, N., van Velden, F. H. P., Meeuwis, A. P. W., Konijnenberg, M., Gotthardt, M., de Jong, H. W. A. M., & Segbers, M. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-0278-3 · Cited by 64 · see citing works

Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen

Kulkarni, H., Singh, A., Langbein, T., Schuchardt, C., Müeller, D., Zhang, J., Lehmann, C., & Baum, R. P. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180308 · Cited by 61 · see citing works

Deep-Learning Generation of Synthetic Intermediate Projections Improves 177Lu SPECT Images Reconstructed with Sparsely Acquired Projections

Rydèn, T., van Essen, M., Marin, I., Svensson, J., & Bernhardt, P. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245548 · Cited by 60 · see citing works

Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function

Rosar, F., Kochems, N., Bartholomä, M. D., Maus, S., Stemler, T., Linxweiler, J., Khreish, F., & Ezziddin, S. (2021) · Cancers · doi:10.3390/cancers13123095 · Cited by 59 · see citing works

[161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617

Schaefer-Schuler, A., Burgard, C., Blickle, A., Maus, S., Petrescu, C., Petto, S., Bartholomä, M. D., Stemler, T., Ezziddin, S., & Rosar, F. (2024) · Theranostics · doi:10.7150/thno.92273 · Cited by 59 · see citing works

213 Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts

Nonnekens, J., Chatalic, K. L. S., Molkenboer‐Kuenen, J. D. M., Beerens, C. E. M. T., Bruchertseifer, F., Morgenstern, A., Veldhoven-Zweistra, J., Schottelius, M., Wester, H., van Gent, D. C., et al. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2155 · Cited by 57 · see citing works

Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients

Paganelli, G., Sarnelli, A., Severi, S., Sansovini, M., Belli, M. L., Monti, M., Foca, F., Celli, M., Nicolini, S., Tardelli, E., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04856-1 · Cited by 57 · see citing works

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Rinscheid, A., Kletting, P., Eiber, M., Beer, A. J., & Glatting, G. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00311-0 · Cited by 56 · see citing works

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy

Rosar, F., Schön, N., Bohnenberger, H., Bartholomä, M. D., Stemler, T., Maus, S., Khreish, F., Ezziddin, S., & Schaefer-Schuler, A. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00385-4 · Cited by 55 · see citing works

Radiation Dosimetry in 177Lu-PSMA-617 Therapy

Jackson, P. A., Hofman, M. S., McIntosh, L., Buteau, J. P., & Kumar, A. S. R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2021.11.003 · Cited by 55 · see citing works

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides

Kletting, P., Schuchardt, C., Kulkarni, H., Shahinfar, M., Singh, A., Glatting, G., Baum, R. P., & Beer, A. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162303 · Cited by 54 · see citing works

Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging

Delker, A., Schleske, M., Liubchenko, G., Berg, I., Zacherl, M. J., Brendel, M., Gildehaus, F. J., Rumiantcev, M., Resch, S., Hürkamp, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06092-1 · Cited by 53 · see citing works

PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients

Ahmadzadehfar, H., Rahbar, K., Essler, M., & Biersack, H. J. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.07.003 · Cited by 53 · see citing works

Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol

Sarnelli, A., Belli, M. L., Iorio, V. D., Mezzenga, E., Celli, M., Severi, S., Tardelli, E., Nicolini, S., Oboldi, D., Uccelli, L., et al. (2019) · Molecules · doi:10.3390/molecules24030621 · Cited by 52 · see citing works

PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies

Giovacchini, G., Giovannini, E., Leoncini, R., Riondato, M., & Ciarmiello, A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3700-x · Cited by 51 · see citing works

Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands

Yılmaz, B., Nişli, S., Ergül, N., Gürsu, R. U., Açıkgöz, Ö., & Çermik, T. F. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.226449 · Cited by 49 · see citing works

Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer

Lesniak, W. G., Boinapally, S., Banerjee, S. R., Azad, B. B., Foss, C. A., Shen, C., Lisok, A., Wharram, B. L., Nimmagadda, S., & Pomper, M. G. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00181 · Cited by 49 · see citing works

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation

Peters, S. M. B., Mink, M. C. T., Privé, B. M., de Bakker, M., de Lange, F., Muselaers, S., Mehra, N., Witjes, J. A., Gotthardt, M., Nagarajah, J., et al. (2023) · EJNMMI Research · doi:10.1186/s13550-023-00952-z · Cited by 48 · see citing works

Neutron-activated theranostic radionuclides for nuclear medicine

Tan, H. Y., Yeong, C. H., Wong, Y. H., McKenzie, M., Kasbollah, A., Shah, M. N. M., & Perkins, A. C. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.09.005 · Cited by 48 · see citing works

Synthesis and Preclinical Evaluation of 177 Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer

Wurzer, A. J., Kunert, J.-P., Fischer, S., Felber, V. B., Beck, R., Rose, F. D., D’Alessandria, C., Weber, W., & Wester, H. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263371 · Cited by 47 · see citing works

Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT

Gosewisch, A., Schleske, M., Gildehaus, F. J., Berg, I., Kaiser, L., Brosch-Lenz, J., Bartenstein, P., Todica, A. S., Ilhan, H., & Böning, G. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05024-1 · Cited by 46 · see citing works

Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis

Seifert, R., Kessel, K., Schlack, K., Weckesser, M., Bögemann, M., & Rahbar, K. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04703-3 · Cited by 45 · see citing works

89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man

Privé, B. M., Derks, Y. H. W., Rosar, F., Franssen, G. M., Peters, S. M. B., Khreish, F., Bartholomä, M. D., Maus, S., Gotthardt, M., Laverman, P., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05661-0 · Cited by 45 · see citing works

Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617

Mahmoudi, E., Pirayesh, E., Deevband, M. R., Amoui, M., Rad, M. G., & Ghorbani, M. (2021) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-021-00713-7 · Cited by 8 · see citing works

Dosimetry of Lu-177 DKFZ-PSMA-617 for the treatment of metastatic prostate cancer using quantitative SPECT/CT

Delker, A., Fendler, W. P., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Bartenstein, P., & Böning, G. (2015) · Journal of Nuclear Medicine · Cited by 1 · see citing works

Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617

Hohberg, M., Eschner, W., Schmidt, M. C., Dietlein, M., Kobe, C., Fischer, T. H., Drzezga, A. E., & Wild, M. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0942-0 · Cited by 85 · see citing works

Kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry

Uijen, M. J. M., Privé, B. M., van Herpen, C. M. L., Westdorp, H., van Gemert, W. A., de Bakker, M., Gotthardt, M., Konijnenberg, M., Peters, S. M. B., & Nagarajah, J. (2023) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001658 · Cited by 32 · see citing works

Determination of Critical Organ Doses with 177Lu Prostate-specific Membrane Antigen Dosimetry in Metastatic Prostate Cancer Treatment

Yilidir, G., & Demır, M. (2024) · Journal of Medical Physics · doi:10.4103/jmp.jmp_12_24 · Cited by 2 · see citing works